This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Lilly's Verzenio Wins FDA Nod for First Line Breast Cancer
by Zacks Equity Research
Lilly's (LLY) new advanced breast cancer treatment Verzenio (abemaciclib) gains FDA approval in first-line setting.
Clovis (CLVS) Q4 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Clovis (CLVS) witnesses narrower year-over-year loss in the fourth quarter. However, the company's revenues miss estimates. Rubraca sales lower.
Pharma Stock Roundup: AZN's Imfinzi Gets 2nd FDA Nod, MRK to Buy Australian Firm
by Zacks Equity Research
Key announcements this week included the FDA approval for a second indication of AstraZeneca's (AZN) Imfinzi and an acquisition offer by Merck (MRK).
Is a Beat in the Cards for Perrigo (PRGO) in Q4 Earnings?
by Zacks Equity Research
Perrigo's (PRGO) product purchases and launches in the Rx segment might boost sales in the coming quarters.
FDA Accepts Acorda's NDA for Parkinson's Disease Candidate
by Zacks Equity Research
FDA accepts Acorda's (ACOR) new drug application (NDA) for its parkinson's disease candidate, Inbrija and it also set an action date of Oct 5, 2018.
Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) out-licenses Generation 2.5 antisense drug to AstraZeneca under a strategic collaboration agreement.
AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion
by Zacks Equity Research
Data shows that AstraZeneca's (AZN) Imfinzi improved PFS by more than 11 months in comparison to placebo in the concerned patient population.
Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the fourth quarter. Demand for Linzess continues to rise.
Foreign Stock Roundup: RDS.A & AZN Impress, NVO & BABA Disappoint
by Swarup Gupta
Losses on Wall Street and falling bond yields weighed on global markets this week.
Job Data Upbeat, Tech Companies Post Modest Q4 Earnings
by Zacks Equity Research
Job Data Upbeat, Tech Companies Post Modest Q4 Earnings
Jobs Report Hits 200K, Unemployment 4.1%; Plus More Q4 Earnings
by Mark Vickery
While this 200K number is higher than the analyst consensus of roughly 180K (analyst for months have been expecting 180K new jobs), it is below the ADP (ADP) payroll report released Wednesday morning.
AstraZeneca (AZN) Beats on Q4 Earnings, Guides for 2018
by Zacks Equity Research
AstraZeneca (AZN) beats earnings estimates in fourth quarter on higher product revenues.
Merck vs. Sanofii: Which Stock Is Better Pre-Q4 Earnings?
by Zacks Equity Research
With Merck and Sanofi scheduled to report on Feb 2 and Feb 27, respectively, this may be a good time to figure out which of these is a better stock.
Allergan (AGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While Allergan's (AGN) Q4 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products will hurt sales.
Alkermes Submits NDA for Depression Candidate to the FDA
by Zacks Equity Research
Alkermes (ALKS) files a new drug application to the FDA for ALKS 5461's effective use in the adjunctive treatment of major depressive disorder (MDD).
Can Merck (MRK) Deliver a Positive Surprise in Q4 Earnings?
by Zacks Equity Research
Merck's (MRK) new products like Keytruda and Bridion are likely to drive sales in the fourth quarter. However, headwinds remain in the form of genericization of key drugs and increasing competition.
AstraZeneca's Triple Combo COPD Inhaler Positive in Phase III
by Zacks Equity Research
AstraZeneca (AZN) announces positive top-line results from the phase III KRONOS study on the triple combination therapy PT010 for severe COPD patients.
Merus' Antibody Candidate in Phase II Breast Cancer Study
by Zacks Equity Research
Merus (MRUS) initiates a phase II study to evaluate its most advanced pipeline candidate in advanced breast cancer.
Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Infinity Provides Update on Lead Candidate, Issues 2018 View
by Zacks Equity Research
Infinity (INFI) announces the achievement of some development milestones for its lead pipeline candidate- IPI-549 and issued financial guidance for 2018.
Is a Beat in the Cards for AbbVie (ABBV) in Q4 Earnings?
by Zacks Equity Research
Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q4.
The Zacks Analyst Blog Highlights: AbbVie, Merck & Co. and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Merck & Co. and AstraZeneca
3 Large Cap Pharma Stocks to Beat Earnings This Quarter
by Zacks Equity Research
The fourth-quarter outlook for Pharma stocks looks bright.
AstraZeneca's PARP Inhibitor Lynparza Gets Approval in Japan
by Zacks Equity Research
AstraZeneca's (AZN) PARP inhibitor, Lynparza, receives approval for treating ovarian cancer in Japan, following its label expansion in the United States.
Foreign Stock Roundup: Taiwan Semiconductor Beats, Shell Buys Stake in Silicon Ranch
by Swarup Gupta
Global markets largely echoed Wall Street's fortunes over last week.